This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Steris (STE) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Strategic Acquisitions to Support STERIS Stock Amid Macro Issues
by Zacks Equity Research
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
STERIS Gains From Expanded Product Offerings Amid Macro Issues
by Zacks Equity Research
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
Reasons to Retain STE Stock in Your Portfolio Now
by Zacks Equity Research
STERIS' strong prospects in the healthcare business bode well for investors.
Why Is Steris (STE) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Alliances to Support STERIS Stock Despite Macro Issues
by Zacks Equity Research
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
Why Steris (STE) International Revenue Trends Deserve Your Attention
by Zacks Equity Research
Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket
by Zacks Equity Research
STERIS' second-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of both margins is concerning.
Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Steris (STE) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 1.42% and 0.58%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Steris (STE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 10.26% and 0.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STE Gears Up for Q2 Earnings: Here's What You Need to Know
by Zacks Equity Research
STERIS' second-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog.
Steris (STE) Up 3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain STERIS Stock in Your Portfolio for Now
by Zacks Equity Research
STE's strong prospects in the healthcare business arm bode well for investors.
Don't Overlook Steris (STE) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Review Steris' (STE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.
Steris (STE) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Steris (STE) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 1% and 1.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 12.96% and 7.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Steris (STE) Q1 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Here's How STERIS (STE) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.
STERIS (STE) AST Business Expands, New Offerings Aid Growth
by Zacks Equity Research
STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Should You Hold STERIS (STE) Stock Now? Here's What to Consider
by Zacks Equity Research
STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.